Interactions of Glucose Metabolism and Chronic Heart Failure

被引：20

作者：

Clodi, M. ^{[2
]}

Resl, M. ^{[2
]}

Stelzeneder, D. ^{[2
]}

Pacini, G. ^{[3
]}

Tura, A. ^{[3
]}

Moertl, D. ^{[1
]}

Struck, J. ^{[5
]}

Morgenthaler, N. G. ^{[5
]}

Bergmann, A. ^{[5
]}

Riedl, M. ^{[2
]}

Anderwald-Stadler, M. ^{[4
]}

Luger, A. ^{[2
]}

Pacher, R. ^{[1
]}

Huelsmann, M. ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Cardiol, A-1090 Vienna, Austria

[2] Med Univ Vienna, Dept Endocrinol & Metab, A-1090 Vienna, Austria

[3] CNR, Inst Biomed Engn, Metab Unit, Padua, Italy

[4] Hietzing Hosp, Med Dept Metab Dis & Nelphrol 3, Vienna, Austria

[5] BRAHMS AG, Res & Dev, Hennigsdorf, Germany

来源：

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES | 2009年 / 117卷 / 03期

关键词：

cardiovascular incidences; metabolic features; obesity; ASSESSING INSULIN SENSITIVITY; PLASMA ADRENOMEDULLIN LEVELS; NATRIURETIC PEPTIDE; SKELETAL-MUSCLE; FIBER-TYPE; IMMUNOLUMINOMETRIC ASSAY; VASOPRESSIN PRECURSOR; HYPERTENSIVE PATIENTS; RESISTANCE; COPEPTIN;

D O I：

10.1055/s-2008-1081211

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: We evaluated insulin sensitivity and beta cell function in patients with chronic heart failure (CHF), and investigated a possible correlation of these metabolic parameters with specific biomarkers of heart failure. Additionally, we investigated the effects of two angiotensin receptor blockers (ARBs), namely telmisartan and candesartan, that were administered over a 5 month treatment period, as additional therapy to standard care. Methods and Results: The study group consisted of 94 CHF patients. Insulin sensitivity (OGIS index) and insulin secretion parameters were investigated by frequently sampled oral glucose tolerance tests and consecutive mathematical modelling. In total, 94.6 % of patients had clinically overt diabetes, impaired glucose tolerance or insulin resistance at the time of enrolment HbA1c was found to correlate to NT-proBNP, MR-proADM, CT-proET-1, and MR-proANP, but not to Copeptin. NT-proBNP correlated inversely to OGIS. None of the metabolic parameters were altered significantly after candesartan or telmisartan treatment in either the patient or standard care group. Conclusion: Insulin sensitivity and insulin secretion are impaired in CHF and biomarkers of heart failure and atherosclerotic disease correlate to glucose metabolism.

引用

页码：99 / 106

页数：8

共 60 条

[31] Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin [J].

Morgenthaler, NG ;

Struck, J ;

Alonso, C ;

Bergmann, A .

CLINICAL CHEMISTRY, 2006, 52 (01) :112-119

[32] Immunoluminometric assay for the midregion of pro-Atrial natriuretic peptide in human plasma [J].

Morgenthaler, NG ;

Struck, J ;

Thomas, B ;

Bergmann, A .

CLINICAL CHEMISTRY, 2004, 50 (01) :234-236

[33] Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay [J].

Morgenthaler, NG ;

Struck, J ;

Alonso, C ;

Bergmann, A .

CLINICAL CHEMISTRY, 2005, 51 (10) :1823-1829

[34] Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure [J].

Pacher, R ;

Stanek, B ;

Hulsmann, M ;

KollerStrametz, J ;

Berger, R ;

Schuller, M ;

Hartter, E ;

Ogris, E ;

Frey, B ;

Heinz, G ;

Maurer, G .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 27 (03) :633-641

[35] Methods for clinical assessment of insulin sensitivity and β-cell function [J].

Pacini, G ;

Mari, A .

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 17 (03) :305-322

[36] INSULIN RESISTANCE AND HYPERINSULINEMIA IN PATIENTS WITH CHRONIC CONGESTIVE-HEART-FAILURE [J].

PAOLISSO, G ;

DERIU, S ;

MARRAZZO, G ;

VERZA, M ;

VARRICCHIO, M ;

DONOFRIO, F .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1991, 40 (09) :972-977

[37] Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma [J].

Papassotiriou, Jana ;

Morgenthaler, Nils G. ;

Struck, Joachim ;

Alonso, Christine ;

Bergmann, Andreas .

CLINICAL CHEMISTRY, 2006, 52 (06) :1144-1151

[38] Peroxisome proliferator-activated receptor-γ:: therapeutic target for diseases beyond diabetes:: quo vadis? [J].

Pershadsingh, HA .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (03) :215-228

[39] APPLICATION OF PRAZOSIN IS ASSOCIATED WITH AN INCREASE OF INSULIN SENSITIVITY IN OBESE PATIENTS WITH HYPERTENSION [J].

POLLARE, T ;

LITHELL, H ;

SELINUS, I ;

BERNE, C .

DIABETOLOGIA, 1988, 31 (07) :415-420

[40] Metabolic characteristics of glucose intolerance: The critical role of obesity [J].

Sainaghi, P. P. ;

Castello, L. ;

Bergarnasco, L. ;

Schianca, G. P. Carnevale ;

Bartoli, E. .

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2008, 116 (02) :86-93

← 1 2 3 4 5 6 →